Paeds Cases · allergy-and-immunology
Counsel a family on a new X-linked agammaglobulinaemia diagnosis — OSCE
OSCE communication and shared-planning station: explaining a new antibody-deficiency diagnosis to a family, the need to confirm the defect with a functional vaccine response and genetic testing before starting immunoglobulin, what lifelong immunoglobulin replacement involves, the family implications of carrier testing, and the generally good prognosis with consistent therapy — while addressing fear and avoiding the over-diagnosis trap.
On this page & tools
Target exams
Candidate brief
You have eight minutes to counsel the parents of a nine-month-old boy in whom you suspect X-linked agammaglobulinaemia. The diagnosis is not yet genetically confirmed. Use a structured, honest, empathic approach. [1] [2]
Key teaching and communication objectives
Acknowledge and validate the parents' fear and guilt before delivering information. Explain that the condition is genetic but not anyone's fault, that it affects the part of the immune system that makes antibodies, and that with consistent treatment the prognosis is good. [2] [3]
Explain the next steps in plain language: a functional vaccine response test and genetic testing to confirm the specific diagnosis, because the right treatment depends on confirming the defect rather than acting on a single number alone. Address the online concern honestly: in some babies a low antibody level is a self-limiting maturational phase, but the combination of absent tonsils, absent B cells, and recurrent deep infection in a boy points to a specific genetic condition that does not resolve on its own. [1] [4]
Describe what immunoglobulin replacement involves (regular infusions to replace the antibody his body cannot make), that it is lifelong, and that it is usually well tolerated. Mention the family implications: carrier testing for the mother's female relatives, because each carrier son has a one-in-two chance of being affected. [2] [3]
Close with a shared plan and a clear next appointment, and an offer of written information and contact with a patient-support organisation. [3]
References
- [1]Bousfiha A, Moundir A, Tangye SG, et al. The 2022 Update of IUIS Phenotypical Classification for Human Inborn Errors of Immunity. J Clin Immunol, 2022.PMID 36198931
- [2]Winkelstein JA, Marino MC, Lederman HM, et al. X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine (Baltimore), 2006.PMID 16862044
- [3]Bonilla FA. Personalized therapy for common variable immunodeficiency. Allergy Asthma Proc, 2020.PMID 31888779
- [4]Seidel MG, Kindle G, Gathmann B, et al. The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity. J Allergy Clin Immunol Pract, 2019.PMID 30776527